Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 112640
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112640
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112640
Artificial intelligence in the management of inflammatory bowel disease: What’s next?
Anthony J Bilotta, Jennifer A Trebilcock, Nicholas J Hebda, Charanpreet K Sasan, Katherine M Cooper, Department of Medicine, UMass Chan Medical School, Worcester, MA 01655, United States
Katherine M Cooper, Department of Medicine, Division of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA 02114, United States
Abbas H Rupawala, Department of Medicine, Division of Gastroenterology and Hepatology, UMass Chan Medical School, Worcester, MA 01655, United States
Co-corresponding authors: Katherine M Cooper and Abbas H Rupawala.
Author contributions: Bilotta AJ revised the manuscript; Bilotta AJ and Rupawala AH conceptualized and designed the review; Bilotta AJ, Trebilcock JA, Hebda NJ, and Sasan CK performed the literature search; Bilotta AJ, Trebilcock JA, Hebda NJ, Sasan CK, and Cooper KM interpreted the data and drafted the manuscript; Bilotta AJ, Trebilcock JA, and Hebda NJ created the figures; Cooper KM and Rupawala AH provided critical revisions, they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: Dr. Rupawala reports personal fees from Abbvie, personal fees from Pfizer, personal fees from Takeda, personal fees from BMS, outside the submitted work. All other authors have no conflicts to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Katherine M Cooper, MD, Department of Medicine, UMass Chan Medical School, 55 Lake Ave North, Worcester, MA 01655, United States.
Received: August 4, 2025
Revised: August 24, 2025
Accepted: December 3, 2025
Published online: March 5, 2026
Processing time: 194 Days and 1.5 Hours
Revised: August 24, 2025
Accepted: December 3, 2025
Published online: March 5, 2026
Processing time: 194 Days and 1.5 Hours
Core Tip
Core Tip: Inflammatory bowel disease (IBD) is a chronic relapsing-remitting autoimmune disorder of the gastrointestinal tract. The management of IBD is complex and relies on subjective interpretation of invasive and non-invasive assessments to guide therapeutic decisions. Artificial intelligence (AI) is emerging as a potential tool to standardize the assessment of IBD and personalize therapeutic selection. This article highlights recent advances in AI in IBD with a focus on endoscopy, non-invasive imaging, histology, AI chatbots, therapeutic prediction models and current barriers to widespread implementation of AI in clinical practice.